Live from the NIH registry
Studies recruiting near Oklahoma City right now
Top 25 of 644 recruiting studies, sorted by proximity — each links to its official registry page
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: SWOG Cancer Research Network
Evaluation of the MuSICCA for Measuring Awareness
Disorder of Consciousness
N/A
Observational 80 participants sought
Bethany Children's Health Centre — Bethany, Oklahoma (7.6 mi)
· Sponsor: The Children's Trust, United Kingdom
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Phase 3
Interventional 428 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: NRG Oncology
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Phase 1, Phase 2
Interventional 460 participants sought
OU Health University of Oklahoma Medical Center ( Site 7000) — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Sameek Roychowdhury
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Phase 1
Interventional 96 participants sought
Dren Investigational Site — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Dren Bio
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura
N/A
Observational 450 participants sought
University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901 — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Insel Gruppe AG, University Hospital Bern
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
N/A
Interventional 105 participants sought
Oklahoma Heart Hospital — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Medtronic Cardiac Rhythm and Heart Failure
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: NRG Oncology
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: AstraZeneca
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Liver Fibrosis, Hepatic Cirrhosis
Phase 2
Interventional 104 participants sought
Research Site — Yukon, Oklahoma (14.3 mi)
· Sponsor: AstraZeneca
The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer
Head and Neck Cancers
N/A
Observational 59 participants sought
Stephenson Cancer Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: University of Oklahoma
Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
Peripheral Arterial Disease
N/A
Observational 14,000 participants sought
Oklahoma University Health Science Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Baylor Research Institute
Neuromodulation of Inflammation and Endothelial Function
Systolic Heart Failure
N/A
Interventional 158 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: University of Oklahoma
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Phase 3
Interventional 200 participants sought
OUHSC (University of Oklahoma Health Sciences Center) — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: CSL Behring
Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY)
Cigar Smoking, Tobacco Use
N/A
Interventional 300 participants sought
University of Oklahoma Health Campus — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: University of Oklahoma
Meloxicam in Mohs Micrographic Surgery
Postoperative Pain, Acute, Skin Cancer
Phase 4
Interventional 300 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: University of Oklahoma
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Obesity or Overweight
Phase 3
Interventional 300 participants sought
Lynn Health Science Institute — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Amgen
Stress Hydrocortisone In Pediatric Septic Shock
Septic Shock
Phase 3
Interventional 500 participants sought
The Children's Hospital at Oklahoma University Medical Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Jerry Zimmerman
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Neurogenic Detrusor Overactivity
Phase 2, Phase 3
Interventional 71 participants sought
University of Oklahoma — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Urovant Sciences GmbH
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: SWOG Cancer Research Network
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian Cancer, Fallopian Tube Cancer
Phase 1, Phase 2
Interventional 30 participants sought
OU Health, Stephenson Cancer Center — Oklahoma City, Oklahoma (0.2 mi)
· Sponsor: Imunon